Genmab surged to record highs after petosemtamab plus Keytruda reduced the risk of death by about half versus Keytruda alone in first-line head and neck squamous cell carcinoma with PD-L1 positivity. In an early analysis, the combination met dual main objectives on response rates and survival, marking another positive late-stage readout for the company.